Veteran entertainer and Tony Award winner Bernadette Peters will headline the 10th annual “Broadway Belts for PFF!” event to raise funds to fight pulmonary fibrosis (PF). Set for Feb. 24 in New York City, the star-studded evening of music, comedy, and performance is the single-largest fundraiser for…
Reducing the decline of forced vital capacity (FVC), a measure of lung function, can improve the quality of life, and lower the mortality rates and financial burden of patients with idiopathic pulmonary fibrosis (IPF), a new study has found. The study, titled “Forced Vital Capacity (FVC) decline,…
The U.S. Food and Drug Administration (FDA), a vast government bureaucracy, employs about 17,500 people and had a budget of $5.7 billion in 2019. Yet even with its enormous resources, the FDA these days relies more and more on patients to…
A software program called CALIPER may be useful in predicting the progression of idiopathic pulmonary fibrosis (IPF) and the effectiveness of antifibrotic treatment based on lung images taken through high-resolution computed tomography (HRCT), researchers found. The study,…
Changes in blood levels of surfactant protein-A (SP-A) — immune proteins most abundant in the lungs — can help predict treatment outcomes with anti-fibrotic therapies, including Esbriet and Ofev, in people with idiopathic pulmonary fibrosis (IPF), a study found. According to the new study, serial measurements…
The gleaming new Dutch headquarters of the European Medicines Agency (EMA), fronting Domenico Scarlattilaan in Amsterdam’s suburban Zuidas business district, finally opened for business last month — just over two years after the European Union decided to relocate the EMA to the Netherlands in the wake of Brexit.
Prolidase deficiency, an inherited enzymatic disease, may cause combined pulmonary fibrosis and emphysema (CPFE) syndrome in adulthood, a case study suggests. The report, “Prolidase deficiency: a new genetic cause of combined pulmonary fibrosis and emphysema syndrome in the adult,” was published in the European…
A high number of bacteria in the lungs of people with idiopathic pulmonary fibrosis (IPF) is linked to disease progression and to an increased risk of mortality, a study found. The study, “Bacterial burden in the lower airways predicts disease progression in idiopathic pulmonary fibrosis and…
A new technique to create lung cells from other, more easily accessible cell types could be useful for understanding diseases like idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). The technique was described in an article, “Reconstructed Single-Cell Fate Trajectories Define Lineage Plasticity…
The European Patent Office (EPO) has issued a “notice of intent” to grant a patent to MN-001 (tipelukast), MediciNova’s investigational oral therapy for idiopathic pulmonary fibrosis (IPF). Once issued, the patent will…
Get regular updates to your inbox.
